Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
复制标题
乌特克单抗和维多珠单抗在老年克罗恩病患者中的真实有效性和安全性。
DOI：
10.1007/s12664-023-01391-3
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Click,Benjamin
中科院分区：
文献类型：
--
作者：
Garg,Rajat;Aggarwal,Manik;Mohammed,Abdul;Achkar,JeanPaul;Lashner,Bret;Philpott,Jessica;Cohen,Benjamin;Qazi,Taha;Rieder,Florian;Regueiro,Miguel;Click,Benjamin
研究报告称乌特克单抗 (UST) 和维多珠单抗 (VDZ) 在治疗克罗恩病 (CD) 方面具有良好的疗效和安全性，但缺乏老年 CD 患者的有效性和安全性数据。我们回顾性分析了 78 名老年患者（UST 和 VDZ 各 39 名），发现尽管既往生物制剂暴露比例较高，但接受 UST 和 VDZ 治疗的患者的临床反应、缓解和粘膜愈合率相似。 UST 和 VDZ 似乎对这种 CD 危险人群有效且安全。需要进一步的大型研究来验证我们的发现。
Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.